Cholangiocarcinoma Foundation Hails Milestone in Effort to Advance new Treatment for IDH1-positive Cholangiocarcinoma Patients as Agios Announces New FDA Filing for TIBSOVO®

“This is an important milestone for this community and specifically for patients with an IDH1 mutation.”